Study of glucagon response and its association with glycemic control and variability after administration of ipragliflozin as an adjunctive to insulin treatment in patients with type 1 diabetes (Suglat-AID)-Reference-Cited by-同舟云学术

Study of glucagon response and its association with glycemic control and variability after administration of ipragliflozin as an adjunctive to insulin treatment in patients with type 1 diabetes (Suglat-AID)

Published:2021-09 Issue:9 Volume:2 Page:e0135
ISSN:2691-3895
Container-title:Medicine: Case Reports and Study Protocols
language:en
Short-container-title:

Author:

Nakamura Yuta,Horie Ichiro,Tashiro Shigeki,Kobayashi Masaki,Kitamura Tadahiro,Kusunoki Yoshiki,Nishida Kenro,Yamamoto Akane,Hirota Yushi,Fukui Tomoyasu,Sekiguchi Dan,Maeda Yasutaka,Minami Masae,Matsui Takanori,Kawakami Atsushi,Abiru Norio

Funder

astellas pharma inc.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Psychiatry and Mental health

Reference34 articles.

1. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018;Foster;Diabetes Technol Ther,2019

2. SGLT-2 inhibitors: a new mechanism for glycemic control;Chao;Clin Diabetes,2014

3. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials;Yamada;Diabetes Obes Metab,2018

4. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial;Dandona;Lancet Diabetes Endocrinol,2017

5. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial;Mathieu;Diabetes Care,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in clinical research on glucagon;Diabetology International;2024-03-23

2. Glucagon secretion and its association with glycaemic control and ketogenesis during sodium‐glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open‐label, prospective study;Diabetes, Obesity and Metabolism;2024-01-22